Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a research note issued to investors on Sunday. They presently have a $38.00 target price on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price would suggest a potential upside of 76.50% from the stock’s current price.

A number of other research firms also recently commented on ADMS. BidaskClub upgraded Adamas Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 23rd. Mizuho reiterated a “buy” rating and issued a $26.00 price objective on shares of Adamas Pharmaceuticals in a report on Tuesday, September 5th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $30.00 price objective on shares of Adamas Pharmaceuticals in a report on Friday, September 1st. They noted that the move was a valuation call. Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a report on Wednesday, August 9th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $45.00 price objective on shares of Adamas Pharmaceuticals in a report on Sunday, May 28th. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $33.00.

Adamas Pharmaceuticals (NASDAQ:ADMS) opened at 21.53 on Friday. The stock’s market cap is $484.73 million. Adamas Pharmaceuticals has a 1-year low of $12.10 and a 1-year high of $22.58. The firm has a 50-day moving average price of $18.00 and a 200 day moving average price of $17.19.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by ($0.12). Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.03 million. During the same quarter last year, the company earned ($0.78) EPS. Adamas Pharmaceuticals’s revenue for the quarter was down 90.9% compared to the same quarter last year. On average, equities research analysts anticipate that Adamas Pharmaceuticals will post ($3.79) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/17/needham-company-llc-reaffirms-buy-rating-for-adamas-pharmaceuticals-inc-adms.html.

In related news, major shareholder Great Point Partners Llc sold 380,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 21st. The stock was sold at an average price of $17.08, for a total transaction of $6,490,400.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have sold a total of 731,041 shares of company stock worth $12,476,149 in the last 90 days. 29.00% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC acquired a new stake in Adamas Pharmaceuticals during the 2nd quarter worth approximately $109,000. State Street Corp lifted its position in Adamas Pharmaceuticals by 9.1% during the 2nd quarter. State Street Corp now owns 285,359 shares of the specialty pharmaceutical company’s stock worth $4,990,000 after acquiring an additional 23,708 shares during the period. Bamco Inc. NY lifted its position in Adamas Pharmaceuticals by 45.5% during the 2nd quarter. Bamco Inc. NY now owns 103,200 shares of the specialty pharmaceutical company’s stock worth $1,805,000 after acquiring an additional 32,272 shares during the period. Dimensional Fund Advisors LP lifted its position in Adamas Pharmaceuticals by 11.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 140,481 shares of the specialty pharmaceutical company’s stock worth $2,457,000 after acquiring an additional 14,987 shares during the period. Finally, Virtu KCG Holdings LLC acquired a new stake in Adamas Pharmaceuticals during the 2nd quarter worth approximately $184,000. 69.24% of the stock is owned by institutional investors.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.